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A B S T R A C T
Background: Data about the relationship between chest radiographs and sputum bacillary load, with
treatment outcomes, in patients with extensively drug-resistant tuberculosis (XDR-TB) from HIV/TB
endemic settings are limited.
Methods: Available chest radiographs from 97 South African XDR-TB patients, at the time of diagnosis,
were evaluated by two independent readers using a validated scoring system. Chest radiograph findings
were correlated with baseline sputum bacillary load (smear-grade and culture time-to-positive in MGIT),
and prospectively ascertained clinical outcomes (culture conversion and all-cause mortality).
Results: Radiographic bilateral lung disease was present in 75/97 (77%). In the multivariate analysis only a
higher total radiographic score (95% CI) was associated with higher likelihood of death [1.16 (1.05–1.28)
p = 0.003], and failure to culture convert [0.85 (0.74–0.97) p = 0.02]. However, when restricting analyses to
HIV-infected patients, disease extent, cavitation, and total radiographic scores were not associated with
mortality or culture-conversion. Finally, cavitary, disease extent, and total radiographic scores all
positively correlated with bacterial load (culture time-to-positive).
Conclusions: In endemic settings, XDR-TB radiological disease extent scores are associated with adverse
clinical outcomes, including mortality, in HIV uninfected persons. These data may have implications for
clinical and programmatic decision-making and for evaluation of new regimens in clinical trials.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) remains a global health problem (Dheda et al.,
2015). However, the advent of drug-resistant TB (DR-TB) threatens
to reverse the gains made by national TB programs and is
prohibitively expensive to treat (Pooran et al., 2013; WHO, 2015).
There is also a growing epidemic of extensively drug-resistant TBAbbreviations: BCH, Brooklyn Chest TB hospital; CD4, cluster of differentiation 4;
CRRS, chest radiograph recording and reporting; CXR, chest radiography; DR-TB,
drug-resistant tuberculosis; HIV, human immunodeficiency virus; ICC, intraclass
coefficient; MDR-TB, multidrug-resistant tuberculosis; MGIT, mycobacteria growth
indicator tube; PAS, para-aminosalicylic acid; PET-CT, positron emission
tomography–computed tomography; TB, tuberculosis; TTP, time-to-positive;
WHO, World Health Organisation; XDR-TB, extensively drug-resistant tuberculosis.
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and either capreomycin, amikacin, or kanamycin) (WHO, 2006). It
is estimated that 10% of all MDR-TB patients have XDR-TB (WHO,
2015). Treatment-related outcomes in patients with XDR-TB who
did not receive newer or repurposed drugs, like bedaquiline or
linezolid, are extremely poor (Dheda et al., 2010). Indeed, in a long-
term prospective cohort of 107 XDR-TB patients mortality was 78%
and only 11% of patients had a favourable outcome at 60 months
after diagnosis (Pietersen et al., 2014). Even with bedaquiline
treatment, 30 month outcomes were sub-optimal with culture
conversion rates of 62% (Pym et al., 2016).
Chest radiography is currently used for screening, diagnosis,
and monitoring of response to anti-TB treatment (Rubin, 1995).
Despite being limited by poor specificity and high inter-observer
variability it remains a useful adjunct to clinical and microbiolog-
ical tools. Several quantitative chest radiographic scoring systems
have been developed and some have shown the potential to limit
observer variability and increase the clinical value of the chest
radiograph in TB (Pinto et al., 2013a; Ralph et al., 2010).iety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
ersity from ClinicalKey.com by Elsevier on October 21, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
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radiography at diagnosis are known to be associated with an
increased sputum bacterial load (Perrin et al., 2010), delayed smear
and culture conversion (Ralph et al., 2010; Ozsahin et al., 2011), and
an increased risk of treatment failure (Hesseling et al., 2010; Singla
et al., 2009). There is scanty data about chest radiographic findings
in MDR-TB/HIV co-infected patients (Brust et al., 2013; Lessnau
et al., 1994). Cavities on the baseline chest radiograph in MDR-TB
may be an independent predictor of bacterial load, longer
conversion times (Holtz et al., 2014) and poor outcomes (Jeon
et al., 2009). However, there are hardly any data about chest
radiographic findings in patients with XDR-TB (Cha et al., 2009),
and how these relate to outcomes in XDR-TB (Jeon et al., 2009).
We could find no published data that examined the relationship
between chest radiographyandtreatment-related outcomes inpatients
with XDR-TB from HIV and TB endemic settings where several factors
including diagnostic delay, strain variability, and immunosuppression
could potentially modulate radiographic findings. Moreover, the
relationship between baseline chest radiography and bacterial load in
XDR-TB has, hitherto, not been studied before. In this study we
attempted to discern the relationship between baseline radiographic
findings, bacterial load and treatment outcomes.
Methods
Setting
In this prospective outcomes-based cohort study available
baseline chest radiographs (at the time of XDR-TB diagnosis) from
patients admitted to Brooklyn Chest Hospital (BCH), Cape Town,
South Africa, between October 2008 and June 2012 were evaluated.
At the time of evaluation a limited number of radiographs were
available at the study site because of transfer of patients to
peripheral clinics where CXRs were not accessible and could not be
removed from outlying health facilities. Patients were managed as
in-patients for at least the duration of the intensive phase of
treatment and discharged to clinic treatment and follow up after
four consecutive negative cultures.
Study population
222 patients with XDR-TB admitted to BCH during the period
October 2008 to June 2012 were followed up. 97/222 available
chest radiographs (CXR), dated within 3 months of XDR-TB
diagnosis, were independently scored by two non-specialist
medical doctors. In total, 125 CXRs were unavailable for study
(13/125 were more than 3 months from the date of XDR-TB
diagnosis, 109/125 unavailable as patients transferred out to
peripheral clinics with their CXRs, and 3/125 were unreadable
according to Chest Radiograph Recording and Reporting (CRRS)
criteria) (Den Boon et al., 2005).
XDR-TB treatment regimen and outcomes
Patients received a WHO approved, directly observed, regimen
(WHO, 2016). Bedaquiline and linezolid were not available.
Treatment outcomes were assigned at censor date (31st October
2013) and regarded as favourable (cure or treatment completion)
or unfavourable (default, treatment failure and death). Treatment-
related outcome definitions used were based on Laserson’s
classifications (Laserson et al., 2005).
Ethics statement
Ethics approval was obtained from the University of Cape Town
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The two experienced primary care medical doctors attended a
two day CRRS (Den Boon et al., 2005) chest radiology teaching
course prior to the scoring of CXRs. To further establish consensus
scoring both readers, pilot read consisting of 20 CXRs was done
together with two specialist pulmonologists experienced in TB.
Thus, criteria for calling cavities and disease extent were agreed on
before independent scoring of the CXRs.
The scoring systems applied in this study (Figure 1) include two
horizontal lines that were measured at the lower border of the 2nd
and 5th anterior costochondral junctions resulting in 6 zones. Each
of the 6 zones was given a numerical score for the extent of disease
(disease extent score) and for the number and size of the cavities
(cavity score) present. Any parenchymal or pleural abnormalities
were regarded as diseased and the area involved was estimated as
more than or less than 50% of the total area. Cavities were declared
where there was clear visible ring like opacity of greater than 50%
of the total circumference. Cavities less than 1 cm were not
considered and scored as ‘no cavitation’. A “total score” was
derived by the sum of the total disease extent and total cavitation
scores for all 6 zones.
Statistical analysis
Factors (history of previous multi-drug-resistant, total number
of drugs the organism was resistant to, weight under 50 kg, HIV
status, and CD4 count) known to be associated with treatment
outcomes (mortality and culture conversion) were tested for
association using Wilcoxon-rank sum (for continuous variables)
and Fisher’s exact test (for discrete variables). Anti-retroviral
therapy was not considered as all but 2 HIV-infected patients were
on ARV treatment at the time of XDR-TB diagnosis. A univariate and
multivariate Cox proportional hazards regression model was used
to identify outcome predictors. Selected variables in the multivar-
iate analysis included those with a p-value <0.1 in the univariate
analysis. Culture conversion was assessed via a non-parametric
competing risk model with death as the competing risk. We
calculated medians and IQRs for continuous variables and
frequency (percent) for categorical variables. Multivariate Cox
proportional hazards models for mortality included variables that
were significantly associated with outcome (p < 0.1) and the pre-
specified variables (weight, diabetes, CXR scores, HIV). Statistical
analysis was done in STATA version 13.
Results
Demographics and outcomes
Patient characteristics are summarized in Table 1. A sensitivity
analysis did not show any significant differences between the
study group of 97 patients and the total group of 222 patients with
respect to age, gender, HIV status and CD4 count.
Treatment-related outcomes were dismal: 4/97 (4%) XDR-TB
patients cured and 86/97 (89%) had unfavourable treatment-
related outcomes: 39/86 (45%) died, 40/86 (47%) treatment failed,
and 7/86 (8%) defaulted. Treatment outcomes for 7/97 patients
who transferred out are unclassified. All-cause mortality in the
cohort was 64/97 (66%) however there was no difference in
mortality in HIV-infected compared to non-infected patients [31/
44 (71%) vs 33/53 (62%), p = 0.53)] (Table 2).
Chest radiograph findings
Reliability between the two readers were tested and the
Pearson intra-class coefficient (ICC) showed a “moderate”versity from ClinicalKey.com by Elsevier on October 21, 
sion. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 1. Chest X-ray scoring system.
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correlation of 0.714 (0.62–0.79) for disease extent score.
75/97 (77%) patients, significantly more HIV-uninfected
patients [49/53 (93%), p = < 0.0001)], had bilateral lung diseaseTable 1









Age years (median, IQR) 34 (27–42) 34 (27–37) 35 (2
Gender (male) 63/97 (65%) 23/33 (70%) 40/64
Weight kg
(median, IQR)
50.3 (46–59) 53.2 (48–60) 50 (4
Diabetes mellitus 9/97 (9%) 4/33 (12%) 5/64 
HIV-infected 44/97(45%) 13/33(39%) 31/64
CD4 cells/mm3
(median, IQR)a
123 (70–266) 122 (65–264) 123 (
Previous DR-TB 53/97 (55%) 15/33 (45%) 38/64
Number of drugs resistant
(median, IQR)
11 (8–12) 11 (9–12) 11 (8
Smear-positive 42/97 (43%) 10/33 (30%) 32/64
Culture conversion 25/97 (26%) 20/33 (61%) 5/64 
Time-to-positive (TTP) days
(median, IQR)
15 (11–22) 16 (13–22) 14 (1
Treatment-related outcome: Unfavourable 77/97(79%) 22/33(67%) 55/64
Alive – – – 
Died – – – 
X-ray
Bilateral lung disease 75/97 (77%) 22/33 (67%) 53/64
Cavity Score
(median, IQR)
0.5 (0–1) 0.5 (0–1) 0.5 (0
Disease extent score (median, IQR) 7 (5–10) 5 (5–7) 9 (6–
Total Score
(median, IQR)b
8 (5.5–11.75) 6 (5–8.5) 10 (6
a CD4 cells of the HIV-infected subgroup.
b Total score = disease extent score plus cavitation score.
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had cavitation [37/53 (70%) vs 18/44 (41%)] and the median cavity
score in HIV-uninfected patients was significantly higher com-
pared to HIV-infected patients [1 (IQR 0–2) vs 0 (IQR 0–0.9)utum culture conversion (data are shown as median (IQR) or n (%), unless otherwise
ased 64/97
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7–45) 0.25 36 (29–41) 34 (25–43) 0.51
 (62%) 0.63 17/25 (68%) 46/72 (64%) 0.9
4–58) 0.05 55.25 (52–63) 49.7 (45–57) 0.01
(8%) 0.75 3/25 (12%) 6/72 (8%) 0.89
 (48%) 0.53 15/25 (60%) 29/72 (40%) 0.14
72–266) 0.91 119 (58–207) 124 (92–306) 0.34
 (59%) 0.28 9/25 (36%) 44/72 (61%) 0.05
–12) 1 11.5 (11–12) 10 (8–12) 0.34
 (50%) 0.03 5/25(20%) 37/72 (51%) 0.02
(8%) <0.0001
0–21) 0.08 18 (13–22) 14 (10–21) 0.03
(85%) 0.03
– 20/25 (80%) 13/72 (18%) <0.0001
– 5/25(20%) 59/72 (82%) <0.0001
 (83%) 0.06 14/25 (56%) 61/72 (85%) <0.0001
–1.12) 0.76 0 (0–0.5) 1 (0–2) <0.0001
11) <0.0001 5 (4–7) 9 (6–11) <0.0001
–12) <0.0001 5 (4–7) 10 (6.38–12) <0.0001
sity from ClinicalKey.com by Elsevier on October 21, 
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Table 2






HIV-uninfected n = 53
(55%)
p Value
Age years (median, IQR) 34 (27–42) 36 (32–41) 33 (24–45) 0.17
Gender male 63/97 (65%) 24/44 (55%) 39/53 (74%) 0.08
Weight kg (median, IQR) 50 (46–59) 54 (46–63) 50 (46–55) 0.22
Diabetes mellitus 9/97 (9%) 6/44 (14%) 3/53(6%) 0.32
CD4 106 cells/mm3
(median, IQR)
Previous DR-TB 53/97 (55%) 22/44 (50%) 31/53 (59%) 0.53
Number of drugs resistant (median, IQR) 11(8–12) 11.5 (11–12) 9.5 (8–12) 0.15
Smear-positive 42/97 (43%) 18/44 (41%) 24/53 (45%) 0.78
Culture conversion 25/97 (26%) 15/44 (34%) 10/53 (19%) 0.14
Time-to-positive (TTP) days (median, IQR) 15 (11–22) 15 (11–23) 15 (11–20) 0.54
Treatment-related outcome: Unfavourable 86/97 (89%) 40/44 (91%) 46/53 (87%) 0.12
Died 64/97 (66%) 31/44 (71%) 33/53 (62%) 0.53
X-ray
Bilateral lung disease 75/97 (77%) 26/44 (59%) 49/53 (93%) <0.0001
Cavity Score (median, IQR) 0.5 (0–1) 0 (0–0.9) 1 (0–2) <0.0001
Disease extent score
(median, IQR)
7 (5–10) 6 (4–10) 8 (6–10) 0.08
Total Scorea (median, IQR) 8 (6–12) 7 (4–11) 9 (6–12) 0.02
a Total score = disease extent score plus cavitation score.
68 J.B. te Riele et al. / International Journal of Infectious Diseases 79 (2019) 65–71p = < 0.0001)] (Table 2). Patients with a history of previous DR-TB
were more likely to have bilateral lung disease (p = 0.026) but there
was no significant difference in disease extent (p = 0.68) or cavity
scores (p = 0.42). The respective median total scores, indicating
extent of lung disease and cavitation, and cavity scores were
significantly lower in XDR-TB HIV-infected patients [7 (IQR 4–11)
vs 9 (IQR 6–12), p = 0.02] and [0 (IQR 0–0.9) vs 1 (IQR 0–2);
(p = < 0.0001) (Table 2).
Chest radiographs related to conversion
XDR-TB patients who failed to sputum culture convert did
significantly worse and more had a history of previous DR-TB [44/
72 (61%) vs 9/25 (36%) p = 0.05], smear positive sputum [37/72
(51%) vs 5/25 (20%) p = 0.02], a shorter time-to-positive (days)
sputum culture [14 (IQR 10–21) vs 18 (IQR 13–22) p = 0.03],
bilateral lung disease [61/72 (85%) vs 14/25 (56%) p = < 0.0001] and
death [59/72 (82%) vs 5/25 (20%) p = < 0.0001] (Table 1).
XDR-TB patients who achieved sputum culture conversion had
a significantly lower median total score [5 (IQR 4–7) vs 10 (IQR
6.38–12), (p = < 0.0001)] and essentially no cavitation [0 (IQR 0–
0.5) vs 1 (IQR 0–2) p = < 0.0001] (Table 1). In a multivariate analysis
the total score was found to be inversely associated with
conversion and time to conversion with mortality as a competing
risk factor (0.85 (95% CI 0.74–0.97) p = 0.02) (Table 3). In HIV-
infected patients cavity and total scores did not independently
predict the likelihood of culture conversion.Table 3
Multivariate Cox proportional hazards model of clinical and radiographic factors in
the full cohort associated with culture conversion in the presence of the competing
risk of death.
Full cohort
HR (95% CI) p Value
Age (years) 0.99 (0.95–1.04) 0.79
Weight (kg) 1.03 (0.99–1.07) 0.15
Diabetes mellitus 0.65 (0.14–2.98) 0.58
HIV-infected 1.33 (0.50–3.50) 0.57
Previous DR-TB 0.36 (0.15–0.91) 0.03
X-ray: Total Scorea 0.85 (0.74–0.97) 0.02
a Total score = disease extent score plus cavitation score.
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XDR-TB patients who died were more likely to have smear
positive sputum (p = 0.03) (Table 1). There was no difference
between those alive and deceased with regards time-to-positive
sputum conversion (p = 0.08), cavitation (p = 0.76) and bilateral
lung disease (p = 0.06) (Table 1). However, XDR-TB patients who
died had a significantly higher lung disease extent score [9 (IQR 6–
11) vs 5 (IQR 5–7) p = < 0.0001] and total score [10 (IQR 6–12) vs 6
(IQR 5–805) p = < 0.0001]. The total score was independently
associated with death in those with XDR-TB [1.16 (95% CI 1.05–
1.28) p = 0.003] (Table 4).
Chest radiographs related to bacterial load
There was no difference between HIV-infected and uninfected XDR-
TB patients with regards to time-to-positive sputum (Table 2). Smear
status was not significantly associated with disease extent (p = 0.23) or
cavity scores (p = 0.76). Disease extent and cavity scores were however
associated with time-to-positive (TTP) (both p = < 0.0001). There was a
correlation between the cavity score and TTP (p = 0.038), and the total
score and TPP (p = 0.039) but not between disease extent and TTP
(p = 0.071) although a trend was evident (Figure 2).
Discussion
The key findings of this study in patients with XDR-TB were
that: (i) there was a clear independent correlation between
radiological disease extent and culture conversion; (ii) total
radiological score (disease extent plus cavitation scores) strongly
predicted the risk of death, and (iii) baseline (at diagnosis)
cavitation and disease extent scores correlated with bacterial load.
Both cavity and total scores were significantly lower in HIV-
infected patients and did not independently predict the likelihood
of culture conversion or death in that sub-group. Furthermore, we
have demonstrated the utility of a validated and reliable chest
radiograph scoring system in patients with XDR TB, as we have
documented the inter-reader variability but more importantly
demonstrated biological meaningfulness and relevance given the
correlation with disease outcomes and bacterial load. There are
several implications, which include using the chest radiograph forversity from ClinicalKey.com by Elsevier on October 21, 
sion. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 4
Multivariate Cox proportional hazards model of clinical and radiographic factors associated with risk of death in HIV-infected and uninfected XDR-TB patients.
Full cohort p Value HIV COHORT p Value
HR (95%CI) HR (95%CI)
Weight (kg) 0.98 (0.95–1.01) 0.13 – –
Diabetes mellitus – – 0.23 (0.05–1.02) 0.05
Previous MDR-TB – – 1.89 (0.80–4.45) 0.15
Sputum culture conversion 0.11 (0.03–0.37) <0.0001 0.21 (0.05–0.93) 0.04
TTP(days) 0.99 (0.95–1.04) 0.79 – –
Diagnosis to treatment(days) 1.00 (1.00–1.00) 0.67 0.99 (0.98–1.01) 0.31
X-ray
Unilateral disease 2.05 (0.82–5.14) 0.13 1.26 (0.34–4.67) 0.73
Disease extent score – – 1.19 (0.95–1.48) 0.13
Total radiographic scorea 1.16 (1.05–1.28) 0.003 – –
Dashes = factors not incorporated in the model as the p value was <0.1 in the univariate analysis.
a Total score = disease extent score plus cavitation score.
Figure 2. Scatter plot of chest radiographic scores (cavity, disease extent, and total) and sputum culture time-to-positive (days). Linear regression line for each scatter plot
added to indicate direction of trend. P-value reports results of test for non-zero correlation coefficient.
J.B. te Riele et al. / International Journal of Infectious Diseases 79 (2019) 65–71 69regimen selection (decision-making when deciding to use more
aggressive regimens and potent drugs including bedaquiline and
linezolid), prognosis, and treatment monitoring. Furthermore, its
prognostic value may facilitate the evaluation and pre-selection of
new immunotherapeutic interventions for MDR-TB (conventional
trials can take 5 to 10 years to complete). Indeed, better prognostic
markers are urgently needed to facilitate evaluation studies of new
drugs. PET-CT has recently shown promise as a marker of outcomes
in patients with MDR-TB (Chen et al., 2014; Stelzmueller et al.,
2016). However, this is an expensive and poorly accessible
technology and more data are required to study the utility of a
simple chest X-ray.
Long-term treatment related outcomes were poor with high
mortality and treatment failure (Pietersen et al., 2014), and in
this cohort 89% of XDR-TB patients had died or failed treatment
at the censor date. Similar to previous studies (Pietersen et al.,
2014; Holtz et al., 2014) we found initial culture conversion to
independently predict the risk of death in all XDR-TB patients.
However, cavitary disease also had prognostic value. Cavitation
was first shown to be an independent predictor of time-to-Downloaded for Anonymous User (n/a) at Stellenbosch Univer
2021. For personal use only. No other uses without permissionculture conversion in 167 patients with MDR-TB (Holtz et al.,
2014) and an independent risk factor for poor outcomes in
Korean XDR-TB patients who were HIV-uninfected (Jeon et al.,
2009). Our findings are similar; in the multivariate analysis total
radiographic disease score (disease extent plus cavitation
scores) predicted culture conversion and time-to-culture
conversion with death as a competing risk. We also found that
the total score (disease extent plus cavity scores) strongly
predicted risk of death.
The TTP of Mycobacterium tuberculosis is a more sensitive
indicator of bacterial load than smear status (Epstein et al., 1998).
Patients with more extensive disease and cavitation on chest
radiograph are known to have higher bacillary burdens and shorter
TTPs (Ralph et al., 2010; Perrin et al., 2010). Indeed, we have shown
an inverse relationship between extent of lung disease, cavity
scores, and TTP (Figure 1). Patients who experienced culture
conversion had significantly longer median TTP at diagnosis.
However, in the multivariate analysis TTP did not independently
predict culture conversion. Thus, TTP is likely to be a less powerful
indicator of treatment response in XDR-TB than in drug sensitivesity from ClinicalKey.com by Elsevier on October 21, 
. Copyright ©2021. Elsevier Inc. All rights reserved.
70 J.B. te Riele et al. / International Journal of Infectious Diseases 79 (2019) 65–71TB (Hesseling et al., 2010) or MDR-TB (Holtz et al., 2014)
presumably because of several modulating factors including
fitness, strain variability, higher grade resistance, and possibly
greater pre-existing lung damage in XDR TB.
We found no association between baseline chest radiography
and conversion or mortality in HIV-infected patients with XDR-TB.
The sample size is small but several other factors may explain this
including more likely death from non-TB related causes (amplified
by delayed diagnosis), and that advanced immunosuppression is
associated with less fibrosis and cavitation on the chest radiograph
(despite the higher pulmonary bacterial load) (Long et al., 1991).
Similarly, we found lower chest radiographic scores in HIV-
infected compared to uninfected patients, and limited value to
predict risk of death. Nevertheless, the extent of lung disease was
substantial and in keeping with a group of patients with MDR-TB
(88% HIV-infected) from Tugela Ferry Kwa-Zulu Natal (Brust et al.,
2013).
We highlight the importance of quantitative radiological
analysis as a factor in predicting treatment response and
prognosis in XDR-TB. Indeed, a recent systematic review found
that most chest radiograph scoring systems combine clinical and
radiological data to inform respiratory isolation in a hospital
setting (Pinto et al., 2013b). Pinto et al. (2013a) developed a
numerical scoring system based on CRRS (Den Boon et al., 2005)
with a high negative predictive value in smear negative, smear
positive, and HIV-infected patients as a rule out test where TB is
clinically suspected. However, there is a need for a more simple
and standardized radiological scoring system, irrespective of a
clinical profile, that is suitable for use in HIV-infected and
uninfected patients. We evaluated a user friendly and basic zonal
scoring system that generates a numerical score, and found it to
be a reliable tool. This has promise as a chest radiograph scoring
system for use in clinical out-patient settings and for future
research.
Our study has several limitations. The retrospectively collected
chest X-rays and large number of patients who transferred out to
clinics limited the proportion of patients whose radiographs were
analysed. It is possible therefore that the study group included a
greater proportion of patients with more advanced disease who
remained hospitalised. However, for regulatory (Provincial study
approval structure), resource-based and logistical reasons we were
unable to access the chest radiographs from peripheral clinics, and
a sensitivity analysis showed that the excluded population had
similar characteristics to those included in the study with respect
to age, gender, HIV status and CD4 count. Chest X-rays done closer
to the date of diagnosis may have improved the overall accuracy of
this study. Lastly, evidence of extra pulmonary TB was not included
in the multivariate analysis.
In conclusion, we have shown that quantitative baseline chest
radiographic analysis in XDR-TB was independently associated
with bacterial load and treatment response (culture conversion
and survival). Quantitative chest radiography remains relevant in
the clinical management of HIV-uninfected patients with XDR-TB,
and has implications for the development of a prognostic bio-
clinical score for tuberculosis that could be useful for the
evaluation of new interventions for MDR-TB.
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